|
Sign In to gain access to subscriptions and/or personal tools.
|
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
Jerry S Wolinsky
Department of Neurology, The University of Texas-Houston, Health Science Center, Houston, Texas, USA
Ponnada A Narayana
Department of Radiology, The University of Texas-Houston, Health Science Center, Houston, Texas, USA
Kenneth P Johnson
Department of Neurology, The University of Maryland-Baltimore, Maryland, USA
Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center
After the placebo-controlled extension of the pivotal US trial of glatiramer acetate for the treatment of relapsing multiple sclerosis ended, 208 participants entered an open-label, long-term treatment protocol. Magnetic resonance imaging (MRI) was added to the planned evaluations of these subjects to determine the consequences of long-term treatment on MRI-defined pathology and evaluate its clinical correlates. Of the 147 subjects that remained on long-term follow-up, adequate images were obtained on 135 for quantitative MRI analysis. The initial imaging sessions were performed between June 1998 and January 1999 at 2447+61 days (mean+standard deviation) after the subject's original randomization. Clinical data from a preplanned clinical visit were matched to MRI within 3+51 days. At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1476+63 days, and 69 randomized to active treatment with glatiramer acetate (oGA) were on drug for 2433+59 days. The number of documented relapses in the 2 years prior to entering the open-label extension was higher in the group originally randomized to placebo (oPBO=1.86+1.78, oGA=1.03+1.28; P=0.002). The annualized relapse rate observed during the open-label study was similar for both groups (oPBO=0.27, +0.45 oGA=0.28+0.40), but the reduction in rate from the placebo-controlled phase was greater for those beginning therapy with GA (oPBO reduced by 0.66+0.71, oGA reduced by 0.23+0.58; P=0.0002). One or more gadolinium enhancing lesions were found in 27.4% of all patients (number of distinct enhancements=1.16+2.52, total enhanced tissue volume=97+26 ml). The risk of having an enhancement was higher in those with relapses during the open-label extension (odds ratio 4.65, 95% confidence interval (CI) 2.0 to 10.7; P=0.001). The odds for finding an enhancement was 2.5 times higher for those patients originally randomized to placebo (CI 1.1 to 5.4; P=0.02) compared to those always on glatiramer acetate. MRI-metrics indicative of chronic pathology, particularly measures of global cerebral tissue loss (atrophy), were uniformly worse for those originally on placebo. These observations enrich our long-term follow up of the clinical consequences of treatment with glatiramer acetate to include its apparent effects on MRI-defined pathology. They show that the effect of glatiramer acetate on enhancements is definite, but modest, consistent with the drug's described mechanisms of action, and that a delay in initiating treatment results in progression of MRI-measured pathology that can be prevented.
Key Words: multiple sclerosis • glatiramer acetate • Copaxone • copolymer 1 • magnetic resonance imaging • clinical trial
Multiple Sclerosis, Vol. 7, No. 1,
33-41 (2001)
DOI: 10.1177/135245850100700107
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Bakshi, M. Neema, B. C. Healy, Z. Liptak, R. A. Betensky, G. J. Buckle, S. A. Gauthier, J. Stankiewicz, D. Meier, S. Egorova, et al.
Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale
Arch Neurol,
November 1, 2008;
65(11):
1449 - 1453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Neurology,
July 8, 2008;
71(2):
136 - 144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Lisak
Neurodegeneration in multiple sclerosis: Defining the problem
Neurology,
May 29, 2007;
68(22_suppl_3):
S5 - S12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al.
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
Multiple Sclerosis,
May 1, 2007;
13(4):
502 - 508.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Sarchielli, M. Zaffaroni, A. Floridi, L. Greco, A. Candeliere, A. Mattioni, S. Tenaglia, M. Di Filippo, and P. Calabresi
Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-{beta} 1a, and high doses of immunoglobulins
Multiple Sclerosis,
April 1, 2007;
13(3):
313 - 331.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina
Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo
Brain,
June 1, 2004;
127(6):
1370 - 1378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S Wolinsky and PROMiSe Trial Study Group
The PROMiSe trial: baseline data review and progress report
Multiple Sclerosis,
June 1, 2004;
10(1_suppl):
S65 - S72.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. S Wolinsky and PROMiSe Trial Study Group
The PRO MiSe trial: baseline data review and progress report
Multiple Sclerosis,
May 1, 2004;
10(3_suppl):
S65 - S72.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K P Johnson, B R Brooks, C C Ford, A D Goodman, R P Lisak, L W Myers, A A Pruitt, M A Rizzo, J W Rose, L P Weiner, et al.
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
Multiple Sclerosis,
December 1, 2003;
9(6):
585 - 591.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, G. Comi, D. Ladkani, J. S. Wolinsky, and M. Filippi
Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis
AJNR Am. J. Neuroradiol.,
January 1, 2003;
24(1):
75 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kappos and P. Duda
The Janus face of CNS-directed autoimmune response: a therapeutic challenge
Brain,
November 1, 2002;
125(11):
2379 - 2380.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Chabot, F P Yong, D M Le, L M Metz, T Myles, and V W Yong
Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis
Multiple Sclerosis,
August 1, 2002;
8(4):
299 - 306.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Brain,
August 1, 2002;
125(8):
1676 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology,
April 23, 2002;
58(90084):
S10 - 22.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, G. P. Garmany Jr., J. Halper, W. H. Likosky, F. D. Lublin, D. H. Silberberg, W. H. Stuart, and S. van den Noort
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
Neurology,
January 22, 2002;
58(2):
169 - 178.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rovaris, G. Comi, M. A. Rocca, J. S. Wolinsky, and M. Filippi
Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications
Brain,
September 1, 2001;
124(9):
1803 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
